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The efficacy of the adenosine receptor blocker aminophyl- 
line on exercise capacity in patients with effort ischemia and 
documented coronary artery. disease has been previously 
documented. In this study the effect of aminophylline on 
effort electrocardiographic (ECG) alterations and chest 
pain was tested in eight patients with syndrome X (angina1 
chest pain on effort, ischemic ECG changes during exercise, 
positive dipyridamole test, normal epicardial coronary ar- 
teries on angiography and absence of coronary spasm after 
ergonovine). 
After double-blind, randomized intravenous infusion of 
aminophylline (6 mg/kg body weight over 15 min) or 
placebo (20 ml of saline solution over 15 min), the eight 
patients with syndrome X underwent an upright bicycle 
exercise stress test on 2 consecutive days. After aminophyl- 
line, there was an increase in effort tolerance (aminophyl- 
line 7.7 -C 1.2 min of exercise versus placebo 5.6 + 0.9, p < 
Experimental (1) and clinical (2,3) studies have recently 
outlined a role for primary reduction in coronary supply 
occurring through flow maldistribution as a mechanism of 
effort ischemia in patients with coronary artery disease (I ,2). 
Transmural redistribution of flow distal to coronary stenosis 
during effort may be mediated by endogenous release of 
adenosine, which is likely to play a major role in the 
regulation of coronary resistance (4). In these patients, 
dipyridamole, which acts through an elevation of endoge- 
nous adenosine plasma levels (5) by inhibiting the uptake of 
adenosine across endothelial cells (6), reproduces the symp- 
tomatic, electrocardiographic (ECG) and echocardiographic 
signs of effort-induced ischemia (7). 
Aminophylline, which acts as an antidote to dipyridamole 
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0.01) paralleled by an increase of the rate-pressure product 
(mm Hg x beats/min x l/100) at 0.1 mV of ST segment 
depression or at peak exercise (aminophylline 278 f 55 
versus placebo 230 + 24, p < 0.05). Aminophylline pro- 
voked the abolition of ECG signs of ischemia in all eight 
patients. 
Thus, at a dosage that should effectively inhibit adeno- 
sine receptors, aminophylline infusion exerts a beneficial 
effect on exercise-induced chest pain and ischemia-like 
ECG changes in syndrome X. This effect occurs possibly 
through the prevention of myocardial Row maldistribution 
elicited by inappropriate adenosine release during effort in 
the presence of increased coronary resistance at the level of 
small intramural coronary arteries. This study, however, 
does not document the ischemic nature of effort-induced 
pain and ECG alterations in syndrome X. 
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by blocking adenosine receptors (8,9), exerts beneficial 
effects on exercise-induced ischemia in patients with coro- 
nary artery disease, possibly by preventing myocardial flow 
maldistribution elicited by excessive adenosine release dur- 
ing effort (10). 
Recently, Cannon and Epstein (11) hypothesized that the 
transmural steal phenomenon might also occur in “micro- 
vascular angina.” This is a clinical syndrome of effort- 
induced pain and ischemia-like ECG ST segment depression 
with a documented reduction in flow reserve, angiographi- 
tally normal coronary arteries and absence of coronary 
spasm of large coronary arteries (syndrome X). The site of 
abnormally elevated resistance was proposed to be intramu- 
ral, upstream from the endocardium-epicardium branching 
point, which is not visualized by coronary angiography (12). 
This abnormality would represent the anatomic background 
for the occurrence of the transmural steal phenomenon, 
triggered by arteriolar vasodilation achieved by metabolic or 
pharmacologic stimuli (13,14), although no clear-cut evi- 
dence exists of the ischemic nature of pain and ECG 
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Table 1. Hemodynamic Data in Eight Patients in Rest Conditions and After Placebo or 
Aminophylline Infusion Before Starting the Exercise Test 
Basal Placebo Basal Aminophylline 
Heart rate (beatslmin) 
Diastolic blood pressure 
(mm Hg) 
Systolic blood pressure 
(mm Hg) 
Rate-pressure product 
(mm Hg x beatsimin 
x 10-q 
90~8 89 k 9 91 + 13* 107 + 15 
862 II 86 ? 9 81 ? 11 81 r 10 
134 + 14 134 2 13 128 k 17 125 + IS 
121 2 I8 119~ 18 I16 ? 1st 135 2 29 
*p < 0.01; tp < 0.05. Values are mean * SD 
alterations. If this were true, one would expect that blockade 
of the adenosine receptors, blunting excessive arteriolar 
dilation, might have beneficial effects on exercise capacity in 
these patients. 
The aim of this study was to test whether aminophylline, 
at a dosage inhibiting adenosine receptors, might increase 
exercise capacity in patients with syndrome X. 
Methods 
Study patients. Twelve women, aged 41 to 62 years 
(mean 49.4), were studied; all had chest pain on effort and an 
abnormal exercise test limited by angina with clear-cut 
horizontal or downsloping ST segment depression (~0.20 
mV). All patients had angiographically normal epicardial 
coronary arteries and absence of even minimal luminal 
irregularities, presence of normal global and regional ven- 
tricular function at baseline (by ventriculography and echo- 
cardiography) and absence of coronary spasm on ergonovine 
testing. As an inclusion criterion, all patients also had a 
positive dipyridamole test, with angina1 pain and ECG 
changes similar in type and degree to those observed during 
the exercise stress test, but without any sign of ventricular 
dysfunction detected by echocardiographic monitoring (14). 
In all 12 patients, the parenteral administration of amino- 
phylline, up to 240 mg over 3 min, fully and promptly 
resolved symptoms and ECG abnormalities induced by 
dipyridamole. No patient had taken cardiac medications for 
r7 days. 
No patient had left or right bundle branch block, conges- 
tive heart failure, complex ventricular arrhythmias, history 
of myocardial infarction, evidence of cardiomyopathy, val- 
vular heart disease, left ventricular hypertrophy, systemic 
hypertension, diabetes mellitus, collagen disease, severe 
anemia or polycythemia. Four patients had a history of 
angina at rest. All patients gave informed consent to enter 
the study and the protocol was approved by our institution. 
Study design. Patients performed two exercise stress 
tests on 2 consecutive days. Before each exercise test, they 
received in a double-blind fashion a randomly allocated 
infusion of placebo (20 ml of saline solution over 15 min) or 
aminophylline (6 mg/kg body weight over 1.5 min). Exercise 
was started at 5 min after the end of each infusion. 
Exercise stress test. Patients performed two multistage 
bicycle ergometer tests with an initial work load of 25 W and 
increments of 25 W every 2 min. Electrocardiographic leads 
showing the most obvious ischemic changes during the 
previous exercise test were continuously monitored during 
exercise. A 12 lead ECG and systolic and diastolic pressure, 
obtained by a cuff sphygmomanometer, were continuously 
recorded. Criteria for interrupting the test were 1) ~0.2 mV 
ST segment depression 0.08 s after the J point, or 2) maximal 
age-related heart rate, moderately severe chest pain or 
muscular exhaustion in the absence of ischemia, alone or in 
combination. 
The rate-pressure product (heart rate x systolic blood 
pressure x lo-*) was used as an index of heart work (15) and 
measured at the onset of ischemia (arbitrarily fixed at 0.10 
mV of ST depression) or, in negative tests, at peak exercise. 
Statistical analysis. Values are expressed as mean values 
F 1 SD. Statistical significance was evaluated by the Student 
t test for paired values and by chi square test. A p value 
co.05 was considered significant. 
Results 
Of the 12 patients, 4 were excluded from the study 
because side effects occurred during aminophylline infusion: 
hypotension (decrease in diastolic blood pressure >30 mm 
Hg) in 2, chest pain in 1 and asymptomatic ventricular 
trigeminy in 1. In all cases, side effects promptly disappeared 
when the aminophylline infusion was stopped. 
Rest conditions. In the eight patients who completed the 
study, after placebo infusion there was no significant change 
from the control value in heart rate, systolic blood pressure 
or rate-pressure product. After aminophylline, a slight in- 
crease in heart rate was recorded (Table 1). 
Exercise testing. All eight exercise tests were positive by 
ECG criteria after placebo; none was positive after amino- 
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phylline (p < 0.01). Seven patients experienced angina1 pain 
during the placebo test, and in three of them pain was 
abolished during the test with aminophylline infusion. 
In comparison with placebo, aminophylline effected a 
significant increase in duration of exercise (7.7 2 1.2 versus 
5.6 ? 0.9 min, p < 0.01). The rate-pressure product recorded 
at peak exercise (in negative tests) or at 0.1 mV of ST 
segment depression was also significantly higher after ami- 
nophylline (278 +- 55 versus 230 * 24, p < 0.05). 
Discussion 
Aminophylline in syndrome X. Aminophylline infusion, 
at a dosage effectively blocking adenosine receptors, in- 
creased the effort tolerance and ischemic threshold in eight 
patients with syndrome X. This finding is of pathophysio- 
logic and potential clinical interest. A major problem of all 
studies in patients with a history of chest pain in the absence 
of angiographically assessed coronary artery disease is the 
assumption of homogeneity of cause in all subjects (16): it 
seems unlikely that a syndrome defined in this way would 
have a unique etiology. Therefore, in this study, restrictive 
criteria were adopted to identify a homogeneous subset of 
patients with “syndrome X.” Although the ischemic origin 
of chest pain and related ECG changes in these patients is 
still debated, being favored by some authors (1 l-14,17) but 
rejected by others (18) in spite of the common finding of a 
reduced coronary reserve, we thought it worthwhile to test 
the effect of aminophylline. 
Reduced flow reserve in syndrome X. In these patients 
with reproducible stress-induced ischemic ECG changes, the 
presence of dipyridamole-induced chest pain or ST segment 
depression, or both, reliably identifies a reduction in flow 
reserve (12,19). Epstein and Cannon (20) have hypothesized 
that an abnormally elevated resistance to flow at the level of 
the small intramural coronary arteries, upstream from the 
endocardium-epicardium bifurcation, might induce a suben- 
docardial steal. According to their hypothesis, the abnormal 
resistance to flow would result in maximal dilation of the 
subendocardial arterioles in the rest condition (and in the 
absence of pharmacologic vasodilator stimuli) because of the 
concomitant higher metabolic demand of the subendocar- 
dium. The putative mechanism of the steal as a response to 
pharmacologic or metabolic stimuli, such as dipyridamole 
and pacing or exercise, would be related to the inability of 
the subendocardial arterioles to dilate further versus a 
“normal” dilation of the subepicardial arterioles and the 
consequent decrease in pressure downstream from the site 
of increased resistance, with reduction of flow to the suben- 
docardium. 
Mechanism of aminophylline’s action. Adenosine, which 
plays a major role in regulating coronary resistance, could be 
the trigger of the transmural steal after effort or dipyridamole 
administration. At the dosage employed in this study, ami- 
nophylline effectively inhibits adenosine receptors and, 
according to experimental data, should not elicit beta,- 
adrenergic stimulation. Aminophylline might exert an anti- 
steal action blunting adenosine-mediated excessive hyper- 
emia, which would result in a transmural coronary steal with 
detrimental underperfusion of the subendocardium. Also, 
the stimulation of alpha,-adrenergic receptors might contrib- 
ute to the phenomenon of reverse transmural steal (21-23). 
That mechanism would involve coronary alpha constriction, 
lower coronary flow velocity, diminish pre-arteriolar gradi- 
ents and, therefore, increase perfusion pressure distal to the 
site of elevated resistance, resulting in increased transmural 
perfusion. 
Clinical implications. The finding of this study on the 
effect of aminophylline may have clinical implications be- 
cause aminophylline is also available in oral formulation and 
some patients with syndrome X respond poorly to conven- 
tional medical treatment (24). Although our results are 
compatible with the hypothesis of a transmural steal in 
syndrome X, the actual ischemic nature of pain and ECG 
alterations in these patients remains to be established. 
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